Video
Dr. Abou-Alfa on Significance of RESORCE Trial for HCC
Author(s):
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the significance of the RESORCE trial, which explored regorafenib (Stivarga) versus best supportive care for patients with unresectable hepatocellular carcinoma who progressed after receiving sorafenib (Nexavar).
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the significance of the RESORCE trial, which explored regorafenib (Stivarga) versus best supportive care for patients with unresectable hepatocellular carcinoma (HCC) who progressed after receiving sorafenib (Nexavar).
The RESORCE study is important for the HCC field because it demonstrates that patients have a promising option in the second-line treatment setting, Abou-Alfa explains.
This trial shows encouraging findings compared with prior studies, in which the placebo arms performed better in experimental arms, he adds.
